Adult Acute Myeloid Leukemia Clinical Trial
Official title:
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
2. Study correlation between CD56 and CD11b expression with haematological parameters in
cases of adult AML.
1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could
predict a poor prognosis for AML patients.
2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely
related to the prognosis of AML patients
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01146223 -
Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia
|
N/A | |
| Completed |
NCT01295710 -
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
|
Phase 3 | |
| Completed |
NCT01807091 -
Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
|
N/A | |
| Recruiting |
NCT03114670 -
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
|
Phase 1 | |
| Recruiting |
NCT05429632 -
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
|
Phase 3 | |
| Active, not recruiting |
NCT03226418 -
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
|
Phase 2 | |
| Recruiting |
NCT05262465 -
Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML
|
N/A | |
| Recruiting |
NCT06329999 -
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
|
N/A | |
| Completed |
NCT01484015 -
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
|
Phase 1 | |
| Completed |
NCT01041443 -
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
|
Phase 1 | |
| Completed |
NCT01251575 -
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT06045819 -
Relation Between Venetoclax Plasma Concentration and Remission in Adults With Acute Myeloid Leukemia (PREDICLAX)
|
||
| Withdrawn |
NCT00101140 -
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
|
Phase 2 |